Crossmark

Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China

Published Online: 2020-10-13

Published Print: 2020-12

Authors

Peng, Zhi

Hou, Xingduo

Huang, Yangmu http://orcid.org/0000-0002-3660-1276
Xie, Tong

Hua, Xinyang
Funding

Funding for this research was provided by:

Beijing Municipal Administration of Hospital's Youth Program (20171102)

Clinical Medicine Plus X - Young Scholars Project of Peking University (PKU2019LCXQ020, PKU2018LCXQ018)
License Information

Text and Data Mining valid from 2020-10-13

Version of Record valid from 2020-10-13
More Information

Article History

Received: 25 February 2020

Accepted: 2 October 2020

First Online: 13 October 2020

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current